BC
AZN icon

Bridgefront Capital’s AstraZeneca AZN Stock Holding History

Bridgefront Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,625
Closed -$213K – 625
2024
Q4 		$213K Buy
+1,625
New +$228K 0.07% 477
2024
Q3 		– Sell
-1,770
Closed -$276K – 530
2024
Q2 		$276K Buy
+1,770
New +$266K 0.12% 320
2023
Q1 		– Sell
-1,799
Closed -$244K – 419
2022
Q4 		$244K Buy
+1,799
New +$226K 0.17% 257
2021
Q1 		– Sell
-8,248
Closed -$825K – 675
2020
Q4 		$825K Buy
+8,248
New +$874K 0.28% 90

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Bridgefront Capital's AZN Position: Q1 2025 in Review

Bridgefront Capital sold out of AstraZeneca (AZN) in Q1 2025, closing a stake of 1,625 shares — an estimated $213K sold.

Bridgefront Capital first reported a position in AZN in Q4 2020 and held it in 4 quarters. The position peaked at $825K in Q4 2020. 1,252 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

  • Bridgefront Capital reported no remaining AstraZeneca position as of Q1 2025 after selling out during the quarter.
  • Bridgefront Capital sold 1,625 AstraZeneca shares in Q1 2025, an estimated $213K.
  • Bridgefront Capital first reported a position in AstraZeneca in Q4 2020 and held it in 4 quarters.
  • Bridgefront Capital's AstraZeneca position peaked at $825K in Q4 2020.
  • 1,252 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on Bridgefront Capital's 13F filing for Q1 2025, filed 15 May 2025.